Takeda Pharmaceutical Company Ltd
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Clinical Trials
1.3k
Trial Phases
5 Phases
Drug Approvals
6
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (1017 trials with phase data)• Click on a phase to view related trials
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- Drug: TAK-188
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 223
- Registration Number
- NCT07205718
- Locations
- 🇺🇸
UCLA Health-Santa Monica Cancer Care (Cancer Care - Santa Monica), Santa Monica, California, United States
🇺🇸Yale School of Medicine - Smilow Cancer Hospital - Center for Thoracic Cancers, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists - Lake Nona, Orlando, Florida, United States
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: Placebo tablets
- First Posted Date
- 2025-10-02
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 180
- Registration Number
- NCT07204314
A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Conditions
- Fabry Disease
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 200
- Registration Number
- NCT07187440
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT07129343
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
- Conditions
- Nonsegmental Vitiligo
- Interventions
- Other: Placebo
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 200
- Registration Number
- NCT07108283
- Locations
- 🇺🇸
Dermatology Trial Associates, Bryant, Arkansas, United States
🇺🇸First OC Dermatology, Fountain Valley, California, United States
🇺🇸Center for Dermatology Clinical Research, Inc., Fremont, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 199
- Next
News
Halozyme Acquires Elektrofi for $750M to Expand Ultra-High Concentration Drug Delivery Technology
Halozyme Therapeutics has agreed to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments, gaining access to breakthrough Hypercon microparticle technology.
Ultragenyx Appoints Eric Olson as Chief Business Officer to Lead Rare Disease Pipeline Expansion
Ultragenyx Pharmaceutical appointed Eric Olson as Chief Business Officer and Executive Vice President effective September 22, 2025, following Thomas Kassberg's planned retirement after 14 years with the company.
Crystalys Therapeutics Emerges with $205M Series A to Advance Gout Treatment Dotinurad
Crystalys Therapeutics launched with $205 million in Series A funding to develop dotinurad, a URAT1 blocker for gout treatment that is already approved in Japan, China, Philippines, and Thailand.
Star Therapeutics Secures $125M Series D to Advance Von Willebrand Disease Drug VGA039 Through Phase 3 Testing
Star Therapeutics raised $125 million in Series D funding co-led by Sanofi Ventures and Viking Global Investors to advance its Von Willebrand disease drug VGA039 through late-stage clinical testing.
Takeda Appoints Former Eli Lilly Executive Rhonda Pacheco to Lead U.S. Operations
Takeda has appointed Rhonda Pacheco, former group vice president of U.S. Cardiometabolic Health at Eli Lilly, as president of its U.S. Business Unit effective September 29, 2025.
ArcaScience Secures $7M to Accelerate AI-Driven Drug Safety Evaluation Platform
ArcaScience raised $7 million in seed funding to expand its AI platform that transforms drug benefit-risk assessments from months-long processes to seconds-long computations.
Controlled Release Drug Delivery Market Expands with Major Pharma Investment in Precision Medicine Technologies
Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.
GIST Treatment Pipeline Shows Robust Activity with 28+ Therapies in Development Across Multiple Clinical Phases
DelveInsight's 2025 pipeline analysis reveals 25+ companies developing 28+ therapies for gastrointestinal stromal tumors, indicating strong industry investment in this rare cancer space.
FDA Approves Nipocalimab for Myasthenia Gravis as Pipeline Advances with 20+ Novel Therapies
The FDA approved nipocalimab (Imaavy) in May 2025 as the first therapy targeting the underlying cause of generalized myasthenia gravis in patients aged 12 and older with specific antibodies.
Cosmo Pharmaceuticals and Takeda Renew Multi-Year Manufacturing Agreement for Ulcerative Colitis Treatment
Cosmo Pharmaceuticals N.V. and Takeda have renewed their multi-year manufacturing and supply agreement for Mesalazine MMX 1200 mg, an oral once-daily treatment for ulcerative colitis.